Clozapine Use in a Movement Disorder Clinic.
Clin Neuropharmacol
; 45(4): 95-98, 2022.
Article
in English
| MEDLINE | ID: covidwho-1891237
ABSTRACT
BACKGROUND:
Clozapine is an effective antipsychotic for Parkinson's disease (PD) that does not worsen motor function and can improve tremor. It is approved for PD psychosis in Europe and Australia.OBJECTIVE:
The aim of this study was to report on the use of clozapine in a movement disorder clinic.METHODS:
We report on patients monitored during the COVID-19 pandemic in clinic over a 7-month period.RESULTS:
Sixty-five patients were seen, of whom 50 had PD. Thirty-one were treated for psychosis, 18 for refractory tremor and 1 for levodopa dyskinesias. The remainder had psychotic symptoms with dementia with Lewy bodies (n = 2) or other movement disorders. Four had clozapine discontinued because of sedation and 1 for agranulocytosis. Three had clozapine temporarily halted because of granulocytopenia but were rechallenged successfully.CONCLUSIONS:
When comparing clozapine use in this clinic as compared with others, we deduce that clozapine is likely significantly underutilized in the United States.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Parkinson Disease
/
Psychotic Disorders
/
Antipsychotic Agents
/
Clozapine
/
COVID-19 Drug Treatment
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Clin Neuropharmacol
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS